Gavel with drugs Ifpharmaceutical companies aren't forthright about their role inincreasing list prices, senators on both sides of the aisle willbecome more combative. (Photo: Shutterstock)

Pharmaceutical executives looking to blame drug-plan middlemen for rising prescriptioncosts at a Senate committee hearing this week will be greetedskeptically by lawmakers, said people familiar with the panel'spreparations.

Senior officials from seven pharmaceutical giants are scheduled to appear before the Senate FinanceCommittee on Tuesday to discuss soaring drug prices, which havebecome a lightning rod in Washington. Drug companies have longpinned climbing prescription costs on rebates that pharmacy-benefitmanagers negotiate when agreeing to cover certain medicines.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.